
CLAIMS

1. Use of a compound represented by formula (I):



(I)

or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of a cell proliferative disorder,

wherein the medicament is to be used in such a manner that:

(a) said compound or salt is to be administered twice weekly for 3 weeks,

(b) administration of said compound or salt is to be paused for the following 1 week, and

(c) steps (a) and (b) are to be subsequently repeated at least once,

wherein the cell proliferative disorder is cancer.

2. The use according to claim 1, which is use of a potassium salt of a compound represented by formula (I).

3. The use according to claim 1 or 2, wherein the cell proliferative disorder is a KRAS mutant cancer.

4. The use according to any one of claims 1 to 3, wherein the cell proliferative disorder is a solid cancer.

5. The use according to any one of claims 1 to 4, wherein the dose per administration in step (a) is 3.2 mg.

6. The use according to claim 5, wherein the medicament is to be used in such a manner that prior to step (a):

(1) said compound or salt is to be administered twice weekly at a dose of 3.2 mg per administration; or

(2)

(2a) said compound or salt is to be administered twice weekly for 3 weeks at a dose of 4 mg per administration,

(2b) administration of said compound or salt is to be paused for the following 1 week, and

(2c) steps (2a) and (2b) are to be subsequently repeated at least once.

7. The use according to claim 6, wherein the medicament is to be used in such a manner that prior to step (1) or (2), said compound or salt is to be administered twice weekly at a dose of 4 mg per administration.

8. The use according to any one of claims 1 to 4:

wherein the medicament is to be used in such a manner that:

(A) first, said compound or salt is to be administered twice weekly at a dose of 4 mg per administration,

(B1) next, said compound or salt is to be administered twice weekly at a dose of 3.2 mg per administration,

(C) after which:

(Ca) said compound or salt is to be administered twice weekly for 3 weeks at a dose of 3.2 mg per administration,

(Cb) administration of said compound or salt is to be paused for the following 1 week, and

(Cc) steps (Ca) and (Cb) are to be subsequently repeated at least once; or

wherein the medicament is to be used in such a manner that:

(A) first, said compound or salt is to be administered twice weekly at a dose of 4 mg per administration,

(B2) following which:

(B2a) said compound or salt is to be administered twice weekly for 3 weeks at a dose of 4 mg per administration,

(B2b) administration of said compound or salt is to be paused for the following 1 week, and

(B2c) steps (B2a) and (B2b) are to be subsequently repeated at least once; or

wherein the medicament is to be used in such a manner that:

(A) first, said compound or salt is to be administered twice weekly at a dose of 4 mg per administration,

(B2) following which:

(B2a) said compound or salt is to be administered twice weekly for 3 weeks at a dose of 4 mg per administration,

(B2b) administration of said compound or salt is to be paused for the following 1 week, and

(B2c) steps (B2a) and (B2b) are to be subsequently repeated at

least once,

(C) after which:

(Ca) said compound or salt is to be administered twice weekly for 3 weeks at a dose of 3.2 mg per administration,

(Cb) administration of said compound or salt is to be paused for the following 1 week, and

(Cc) steps (Ca) and (Cb) are to be subsequently repeated at least once.

9. The use according to any one of claims 1 to 3, wherein the cell proliferative disorder is multiple myeloma.

10. The use according to claim 9, wherein the dose per administration in step (a) is 4 mg.

11. The use according to claim 9 or 10, wherein the cell proliferative disorder is an NRAS mutant cancer.

12. The use according to any one of claims 9 to 11, wherein the medicament is to be used in combination with dexamethasone, and wherein the medicament is to be used in such a manner that said compound or salt is to be administered before, simultaneously with or after administration of dexamethasone.

13. The use according to claim 12, wherein dexamethasone is to be administered once weekly at a dose of 20 mg per administration.

14. The use according to any one of claims 1 to 13, wherein the administration of said compound or salt is oral administration.